Navigation Links
Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
Date:12/5/2007

Australian Quarantine & Inspection Service approves permit for NKO(R)

import

LAVAL, QC, Dec. 5 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has received notification from the Therapeutic Goods Administration (TGA) in Australia that Neptune Krill Oil (NKO(R)) has obtained approval as a complementary medicine allowing immediate commercialization in Australia hence New Zealand, which automatically allows TGA approved products.

The Department of Health and Aging of the TGA has accepted and registered, in the Australian Register of Therapeutic Goods, Neptune Krill Oil under the Australian Approved Biological Name "Euphausia superba oil". In addition, the Australian Quarantine and Inspection Service has granted a permit to import quarantine material of NKO(R).

"In Australia and New Zealand complementary medicines are classified as a subset of over-the-counter (OTC) pharmaceuticals," stated Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Considering the very tight regulatory control by the TGA, obtaining complementary medicine approval and the quarantine permit constitute a major breakthrough for Neptune in Australia and New Zealand," she added.

"Physician and other healthcare practitioner recommendations have always had a positive impact on our sales. Bearing in mind that 50% of complementary medicines in Australia are sold through medical recommendations and in pharmacies(1), we are seeking a strategic alliance with a major local partner in order to commercialize NKO(R) in these targeted markets. In order to support penetration in this new market, Neptune expects to be actively participating in the near future with such a partner in a series of medical conventions, seminars and media conferences to introduce the scientific data, clinical research and health benefits of NKO(R) to physicians and other hea
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
11. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Now in ... leaders from around the globe to discuss pain management, preclinical and clinical development of new ... Minneapolis, MN ... Summit , set to take place on October 4th-5th, 2010 in Philadelphia, has been announced., ...
... CAMBRIDGE, England , May 25, 2010 Executives ... announced today,an extension of the agreement under which O2h provides multi-FTE -synthetic,chemistry ... , , ... Head of Chemistry said, "We are happy to have signed,this new contract ...
... EXTON, Pa. , May 25 Fibrocell Science, ... the development of autologous cell therapies for aesthetic, medical and ... with Irish Voice newspaper and ... and Chief Financial Officer Declan Daly as a ...
Cached Biology Technology:Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.'s Declan Daly as 'Irish Life Science 50' Member 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... PROVIDENCE, R.I. [Brown University] It,s been long known ... cells stabbed with spiky, long asbestos fibers, and the image ... cell, like a quivering arrow that,s found its mark. ... be interested in asbestos fibers and other materials at the ...
... ITHACA, N.Y. With an eye toward understanding DNA ... to actually unzip the two strands of DNA. (Nature, online ... processes, including DNA replication, are enzymes called helicases. Acting like ... prompting the strands to "zip" apart. What had been ...
... already led to major shifts in the abundance of commercially ... on September 15 in Current Biology , a Cell ... abundance of species as opposed to their presence or absence ... well on the European shelf than more northerly, cold-adapted species," ...
Cached Biology News:Why carbon nanotubes spell trouble for cells 2For unzipping DNA mysteries -- literally -- Cornell physicists discover how a vital enzyme works 2In rapidly warming seas, some fish lose while others gain 2
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Biology Products: